Pulmonary Medicine

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Jason Ackrivo, MD, MSCE

Respiratory complications are fairly common in patients with neuromuscular disorders, and given their vast impacts on a patient’s prognosis and quality of life, it’s critical to proactively detect and monitor any signs of respiratory decline. To learn more about the symptoms, impacts, and diagnosis of respiratory complications in patients with neuromuscular disorders, Dr. Charles Turck speaks with Dr. Jason Ackrivo. Not only is Dr. Ackrivo the Associate Director of the Fishman Program for Home Assisted Ventilation, but he's also an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Bimaje Akpa, MD

Clinical practice guidelines from the American College of Chest Physicians provide recommendations for managing respiratory complications in patients with neuromuscular diseases, which can help inform our evaluation and treatment decisions. Joining Dr. Charles Turck to break down key insights from the CHEST guidelines and their impacts on clinical practice is Dr. Bimaje Akpa. Dr. Akpa is an Assistant Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at the University of Minnesota.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Hank Mayer, MD

Patients with neuromuscular conditions often exhibit respiratory symptoms that impact their airway clearance and gas exchange, making it increasingly difficult for them to breathe. However, effective assessment techniques and early intervention can help mitigate the progression of this dysfunction, potentially keeping patients from needing extended recovery time or even inpatient care. Joining Dr. Charles Turck to discuss the importance of informed, proactive intervention for respiratory symptoms in patients with neuromuscular conditions is Dr. Hank Mayer. Dr. Mayer is the Medical Director of the Pulmonary Function Laboratory at the Children's Hospital of Philadelphia and a Professor of Clinical Pediatrics at the University of Pennsylvania's Perelman School of Medicine.

Guest: Kathleen M. Buchheit, MD

Guest: Joseph K. Han, MD

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.​3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.​3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia.

References:

1. Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9
2. Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975.
3. van der Veen J, et al. Allergy. 2017;72:282-290.
4. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141.

©2024 Amgen and AstraZeneca. All rights reserved.
US-96000 Last Updated 12/24

Guest: Clete A. Kushida, MD, PhD

Guest: Sally Ibrahim, MD, FAAP

Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.

Guest: Ashwin Basavaraj, MD

Guest: Keren Bakal, MD

Guest: Nathan Falk, MD, MBA, FAAFP

Guest: Amy Springer, NP

Often mistaken for COPD or asthma, bronchiectasis and nontuberculous mycobacteria (NTM) can be difficult to recognize and test for, often delaying diagnosis and effective treatment. However, an emphasis on education and research can help address these diagnostic gaps, and involving a multidisciplinary care team can improve treatment plans and patient outcomes. Joining Dr. Ashwin Basavaraj, Associate Professor of Medicine at NYU Grossman School of Medicine, to talk about how we can optimize the diagnosis and management of bronchiectasis and NTM are Dr. Keren Bakal, Dr. Nathan Falk, and Ms. Amy Springer. Dr. Bakal is a pulmonologist specializing in critical care medicine at Overlook Medical Center and Morristown Medical Center in New Jersey, Dr. Falk is a Professor and the founding Residency Director for Family Medicine at Florida State University, and Ms. Springer is a Senior Nurse Practitioner at NYU Langone Health.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP.

©2025 Amgen and AstraZeneca. All rights reserved.
US-94728 Last Updated 1/25

Host: Isaretta Riley, MD, MPH

Guest: Nicola A. Hanania, MD, MS, FCCP

Guest: Jay Peters, MD

A recent study assessing the impact of implicit bias on uncontrolled asthma treatment found that a patient’s identity and socioeconomic status can unintentionally influence a physician’s decision-making, impacting the quality of care. Additionally, a critical gap exists in clinician awareness and implementation of health equity practices, which play a key role in mitigating these unintended consequences. That’s why Drs. Isaretta Riley, Nicola Hanania, and Jay Peters come together to explore the latest research on unconscious bias in asthma treatment and provide recommendations for more equitable care. Dr. Riley is an Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina; Dr. Hanania is a Professor of Pulmonary Medicine and the Director of Airways Clinical Research Center at Baylor College of Medicine in Houston, Texas; and Dr. Peters is a Professor Emeritus of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of Texas, San Antonio.

This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Host: Jacob Sands, MD

Guest: Julia Rotow, MD

In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Laura Alder, MD

The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.